Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study.

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Abstract Text:

Fifty evaluable patients with advanced colorectal cancer, but without prior chemotherapy or immunotherapy, were randomized to one of two schedules of recombinant gamma-interferon (rGIFN). Twenty-four evaluable patients received rGIFN as a 2-h intravenous infusion daily x 5 every other week at a starting dose of 4.0 x 10(6) IU/m2/day (arm I). Twenty-six evaluable patients received rGIFN as a 24-h continuous intravenous infusion daily x 5 every month at a starting dose of 2.6 x 10(6) IU/m2/day (arm II). Toxicities on both schedules included flu-like symptoms, fevers/rigors, nausea/vomiting, hypotension, leukopenia, hepatotoxicity, nephrotoxicity, diarrhea, anemia, confusion, and ileus. Toxicity appeared to be more severe on arm I. No antitumor responses were observed, with 95% confidence intervals of 0 to 14% for arm I and 0 to 13% for arm II.

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Publishing Authors By Initials

For similar diagnosis: prognosis research abstracts see: diagnosis: prognosis research

PUBMED ID PMID:

MEDLINE DATE:

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of immunotherapy : official journal of the

VOLUME: 10

Page Numbers: 379-82

Journal Abbreviation: J. Immunother.

ISSN: 1053-8550

DAY: 18

MONTH: Oct

YEAR: 1991

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9102704

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Keywords Mesh Terms:

KEYWORDS: Prognosis

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Information

Substance Name: Interferon-gamma, Recombinant

Registry Number: 0

Grant and Affiliation Information for Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study.

AFFILIATION: Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio.

Country: UNITED STATES

AGENCY: United States NCI

GRANT: CA-37429

ACRONYM: CA

MEDLINETA: J Immunother (1991)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study Related Publications

• A modified tracheotomy tube for tracheal stenosis.
• Campylobacter jejuni Biofilms Up-Regulated in the Absence of the Stringent Response Utilize a Calcofluor White-Reactive Polysaccharide.
• Cause and prevention of central nervous system injury in neonates undergoing cardiac surgery.
• Chronic hypoxemia increases ventricular brain natriuretic peptide precursors in neonatal swine.
• Clinical Findings Usually Overlooked in Mucomembranous Enterocolitis.
• Food safety controls in Europe--challenges and opportunities.
• Genetic factors are important determinants of neurodevelopmental outcome after repair of tetralogy of Fallot.
• Hyperglycemia after infant cardiac surgery does not adversely impact neurodevelopmental outcome.
• Industrial health problems in the South.
• Neurodevelopmental outcomes after staged palliation for hypoplastic left heart syndrome.
• Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study.
• Polyphosphate kinase 1 is a pathogenesis determinant in Campylobacter jejuni.
• Prevalence and risk factors for tricuspid valve regurgitation after pediatric heart transplantation.